The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -15.59 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.43 — flag raised, worth a closer lookWatch
- Earnings quality 58/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as UroGen Pharma Ltd. reports it. History and quarterly detail are in the app.
- Jelmyto$94.0M
- Zusduri$15.8M
Leadership changes
From UroGen Pharma Ltd.'s own filings, the day they're filed.
- Don Kim · Chief Financial Officer · departureeff. 2024-10-08
- Christopher Degnan · Chief Financial Officer · appointmenteff. 2024-10-07
- Fred E. Cohen · director · departureeff. 2024-09-12
Latest filings
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-06
- 10-Q · Quarterly report2026-05-06
- DEF 14A · Annual proxy (pay & governance)2026-04-30
- 8-K · Company announcement2026-03-02
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about UroGen Pharma Ltd., every answer cited🔒
- The Intelligence Brief — added when UroGen Pharma Ltd.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.